Literature DB >> 9012352

Dopaminergic neurons protected from degeneration by GDNF gene therapy.

D L Choi-Lundberg1, Q Lin, Y N Chang, Y L Chiang, C M Hay, H Mohajeri, B L Davidson, M C Bohn.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) supports growth and survival of dopaminergic (DA) neurons. A replication-defective adenoviral (Ad) vector encoding human GDNF injected near the rat substantia nigra was found to protect DA neurons from the progressive degeneration induced by the neurotoxin 6-hydroxydopamine (6-OHDA) injected into the striatum. Ad GDNF gene therapy reduced loss of DA neurons approximately threefold 6 weeks after 6-OHDA lesion, as compared with no treatment or injection of Ad lacZ or Ad mGDNF (encoding a biologically inactive deletion mutant GDNF). These results suggest that Ad vector-mediated GDNF gene therapy may slow the DA neuronal cell loss in humans with Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9012352     DOI： 10.1126/science.275.5301.838

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  110 in total

1.  Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease.

Authors:  S M Kulich; C T Chu
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

2.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 3.  Synaptogenesis in the CNS: an odyssey from wiring together to firing together.

Authors:  David W Munno; Naweed I Syed
Journal:  J Physiol       Date:  2003-08-01       Impact factor: 5.182

Review 4.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

5.  The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.

Authors:  Guo-rong Zhang; Xu Li; Haiyan Cao; Hua Zhao; Alfred I Geller
Journal:  Brain Res       Date:  2010-12-21       Impact factor: 3.252

Review 6.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 7.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

8.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

Authors:  Sang Ryong Kim; Tatyana Kareva; Olga Yarygina; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

9.  Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

Authors:  D Suwelack; A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; K Wawrowsky; P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

10.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.